Darin K. Edwards

The paper develops a risk calculator to predict immune escape of SARS-CoV-2 variants and group antigenically related variants to guide vaccine strain selection.

Booster SARS-CoV-2 mRNA vaccine recruits and broadens GC B cell responses targeting a highly conserved site on receptor binding domain of spike glycoprotein.

This study develops and evaluates two mRNA vaccines targeting the LP.8.1 variant of SARS-CoV-2, showing broad neutralization against JN.1-lineage subvariants.

This study maps polyclonal antibody responses to mRNA-1273 and NVX-CoV2373 vaccines using EMPEM, revealing the NTD supersite as an immunodominant epitope vulnerable to variant mutations.

This paper designs multivalent RBD nanoparticle vaccines that overcome immune imprinting and provide broad protection against SARS-CoV-2 variants and sarbecoviruses.

This study evaluates JN.1 and KP.2 mRNA vaccines in mice, showing they elicit strong neutralizing antibodies against JN.1 subvariants and cross-neutralize KP.3, LA.2, and XEC.

This study shows that boosting mice with mRNA vaccines in the ipsilateral or contralateral arm leads to equivalent immune responses and protection against SARS-CoV-2 Omicron.

This study shows that intestinal helminth infection reduces T cell responses to an mRNA SARS-CoV-2 vaccine and weakens protection against Omicron but not the ancestral strain.

This study shows that Omicron variant-matched boosters after prototype mRNA vaccines induce cross-neutralizing antibodies against SARS-CoV-2 and sarbecoviruses by imprinting prior immune responses.